Bladder Cancer and NOS-NO Gene Polymorphisms

Akin Soner Amasyali, Ercan Kazan, Bülent Erol

Akin Soner Amasyali, Ercan Kazan, Department of Urology, Adnan Menderes University School of Medicine, Turkey
Bülent Erol, Bülent Erol, Associate Professor of Urology, Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey

Correspondence to: Bülent Erol MD, Associate Professor of Urology, Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
Email: erolbulent@yahoo.com
Telephone: +905323526564

Received: March 26, 2015 Revised: May 12, 2015
Accepted: May 16, 2015
Published online: June 26, 2015

ABSTRACT

Nitric oxide (NO) is a pleiotropic molecule with a variety of functions. NO may have both pro- and antitumor functions. NO could take part in tumour development and progression. Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may influence the risk of cancer, but the results are still conflicting. Most studied eNOS gene mutations are T-786C, G894T and intron 4a/b polymorphisms in the literature. Environmental factors and genetic susceptibility may contribute to cancer development. Numerous clinical and molecular studies have shown that bladder cancer is a heterogeneous disease. Different chemical carcinogens are associated with similar levels of risk for developing varying grades and stages of bladder cancer, and therefore, carcinogen exposure alone cannot explain the heterogeneity of the disease. Molecular alterations may lead to heterogeneity and are influenced by environmental exposure. There are many genetic polymorphisms in metabolic enzymes, and other genes have been found to be bladder cancer risk factors. But a few studies have evaluated the role of eNOS polymorphisms in this cancer. The objective of this review is to evaluate the role of the eNOS polymorphisms in cancer susceptibility, especially in bladder cancer which is the second most common malignancy of urinary tract.

INTRODUCTION

Bladder cancer is one of the most common cancers in the world. This cancer is the second most common malignancy of urinary tract cancer and fourth most frequent cancer diagnosed in men accounting for 7% of total cancers and the eighth most common cancer in women in the United States[1]. Bladder cancer is a multi-factorial disease that is mediated by both genetic and environmental factors such as occupational chemical exposure, tobacco use, some microorganisms and genetic factors[2].

Nitric oxide (NO) is an important biological molecule with a variety of functions. Nitric oxide synthase (NOS) is the responsible enzyme in NO production from L-arginine. Three main isoforms, derived from separate genes, have been described and named after the cells in which they were first found[3]. These are neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2) and endothelial NOS (eNOS or NOS3)[4]. In the last three decades, the role of NO in tumor cell biology and tumor angiogenesis has been firmly established. NOS isoforms are reported to be present in human solid tumors and tumor cell lines (Table 1). Importance of NOS gene polymorphisms relies on the contradictory role of NO in carcinogenesis. At the present time, several polymorphisms identified in human eNOS gene but a few variations are assumed to have functional importance[5-8]. The G894T variation (rs1799983) may alter eNOS activity or regulation. Several studies reported that some of the eNOS gene polymorphisms are significantly associated with development of several types of cancer[9].

© 2015 ACT. All rights reserved.

Key words: Nitric oxide; Nitric oxide synthase polymorphism; Bladder cancer

Amasyalı AS, Kazan E, Erol B. Bladder Cancer and NOS-NO Gene Polymorphisms. Journal of Nephrology Research 2015; 1(1): 25-29 Available from: URL: http://www.ghrnet.org/index.php/jnr/article/view/1141
NO has multiple physiological functions, including vasodilatation, neuronal transmission, smooth muscle relaxation and immunity and is released by endothelial cells[3,5]. The cellular effect of NO is complex and can be cytoprotective or cytotoxic, depending on its concentration and cellular microenvironment[13]. At low concentrations, NO may exert cytoprotective function through cell homeostasis, muscle relaxation, neurotransmission and platelet function[3,12,13]. Low levels of NO may also protect endothelial cells from exposure to risk factors such as reactive oxygen species (ROS) and tumor necrosis factor-α[14,15]. The specific actions whereby NO protects against ROS may include interacting with metals to prevent the formation of oxygen species, scavenging oxidants, preventing the degradation of metalloproteins and preventing lipid peroxidation[16]. At high concentrations, NO and its derivatives can cause DNA strand breaks and impair the tumor suppressor function of p53, which may lead to carcinogenesis[17,20].

NITRIC OXIDE SYNTASE

eNOS is one of three isoforms of NOS that generates NO in vascular endothelium and is encoded by the eNOS gene which is localized to chromosome 7q35-36[33]. nNOS is located on chromosome 12 and iNOS on chromosome 17[22,23]. The eNOS gene have about 1,500 base pairs of upstream promoter sequence similar to other NOS and include transcription factor-binding sites that mediate regulation by estrogens, shear stress[24]. eNOS generates low levels of the endogenous free radical nitric oxide during the transformation of L-arginine to L-citrulline at the presence of tetrahydrobiopterin (BH4), an essential eNOS cofactor[25]. It has been shown that eNOS regulates blood pressure, platelet aggregation, leukocyte adherence, and vascular smooth muscle cell mitogenesis and angiogenesis[26].

More than 168 polymorphisms have been identified in the eNOS gene[27]. Only three of these polymorphisms, namely 894G>T, intron 4a/b, and -786T>C, seem to be functional, and they have been investigated for their association with the risk of several diseases, predominantly cardiovascular disease[26,29]. Several polymorphisms in eNOS gene have been identified, including a common missense variant at nucleotide position 894 (G894T) in exon 7, resulting in a substitution of glutamic acid to aspartic acid at amino acid position 298. This polymorphism is associated with differing susceptibility to cleavage in eNOS enzyme in transfected cells and human endothelial cells, related to reduced basal NO production[28,31]. Previous studies have shown increased risk of coronary artery disease and hypertension associated with eNOS Glu298Asp genotypes[32,31].

Table 1 Inducible NOS expression in various cancers[22]

| Organ     | Expression of inducible NOS |
|-----------|-----------------------------|
| Colon     | Aberrant crypt foci Adenoma Adenocarcinoma |
| Breast    | Invasive lesions Tumors |
| Prostate  | High-grade prostatic intraepithelial neoplasia Cancer |
| Bladder   | Dysplastic lesions Carcinoma |
| Head and neck | Carcinoma |

NITRIC OXIDE

NO is a very important intercellular messenger molecule. However, previous studies have indicated that NO may have both pro- and antitumor functions, under varied conditions in the course of tumor initiation, development, and progression[14,15] (Figure 1). The pro-tumor property may be related to DNA damage, mutation of tumor suppressor gene p53, promotion of angiogenesis and stimulation of tumor cell blood flow whereas the antitumor effects may be associated with the induction of apoptosis, activation of antioxidant defense, cytostatic effect and immunity[36,37]. The effective NO functions depend, to a great extent, on its concentration, local microenvironment and timing of production. Lancaster et al[38] noted that heterogeneity in the chemical process, biological production of NO and cellular responses to NO, among other factors, might render different biological outcomes related to NO. Elevated levels of all three isoforms of nitric oxide synthase have been found in human solid tumors, indicating that NO is a mediator of tumor progression[39]. The production of NO is part of the macrophages' antitumor immune response mechanism, yet an over-expression of NO levels in tumor cells has been found to correlate with poor clinical outcome[40]. Table 1 summarizes evidence in support of iNOS association during tumor development in humans and animals[39].

Figure 1 The dual role of nitric oxide in cancer biology[28].

NITRIC OXIDE SYNTASE ISOFORMS AND POLYMORPHISMS

NOS isoforms and polymorphisms are reported to be present in human solid tumors and tumor cell lines[39]. Yang et al[4] did not observe a significant relationship between NOS3 Glu298Asp and breast cancer risk, but we did find that this polymorphism was associated with the risk of post-menopausal breast cancer among subgroups of women defined by smoking status or intensity of smoking. Ozturk et al[40] reported that Glu298Asp and VNTR intron 4 polymorphisms in the eNOS gene could be an intriguing factor that modulates an individual’s risk of endometrial carcinoma in Turkish population. Unal et al[41] showed that neither 984G>T nor intron 4a/b polymorphisms were related with gastric cancer. Some studies have found that NOS2A and NOS3 genetic polymorphisms are associated with prostate cancer risk[4,42].

Evidence for NO involvement in tumour biology has been reported from several different forms of cancer both in vitro and in vivo[43]. However, there are conflicting reports whether NO promotes or inhibits tumour growth. Thomae et al, described that low concentrations of NO stimulated endothelial cell growth, whereas high concentrations acted in an inhibitory fashion[44]. This dual effect of NO on cell growth has also been demonstrated in bladder cancer cell lines by Morcos et al[45]. In a study, iNOS expression was found in biopsies from bladder tumours and they found no correlation between the levels of iNOS and tumour grade or stage[46]. NO levels are higher in patients with CIS lesions than in patients with papillary bladder tumours and this increase is also likely due to an elevated expression of iNOS[47]. Furthermore, several studies propose that NO also actively mediate some of the anti tumour effects seen after BCG treatment[48-49]. NO levels are higher in the bladder after BCG treatment and are likely to reflect an increased expression...
of iNOS in bladder urothelial cells and immune competent cells in the submucosa and these findings are in line with previous results implicating that BCG may act through NO/NOS pathways, which is further supported that polymorphisms (eNOS -786T>C polymorphism, eNOS Glu298Asp polymorphism) in the iNOS and eNOS genes may influence treatment outcome for BCG[49], eNOS expression has been demonstrated in the endothelium of bladder tumour vessels and endothelial derived NO, produced by eNOS, has been proposed to promote angiogenesis and cancer invasiveness (48). In vitro studies on bladder cancer cells have suggested a similar role for NO in bladder cancer, promoting cell growth when produced at low concentrations whereas high concentrations result in cytostatic and cytotoxic effects[54,55].

Increased iNOS expression also has been found consistently in bladder cancers[56-58]. In one study, all 94 transitional cell carcinomas examined exhibited some immunostaining for iNOS. All dysplastic lesions adjacent to carcinomas exhibited staining patterns similar to malignant tissue, suggesting that upregulation of iNOS is an early event during bladder carcinogenesis[49]. iNOS expression has been reported in several cancers including bladder cancer[59]. The iNOS (CCTTT)n promoter microsatellite polymorphism at -2.6 kb has been suggested to be associated with gastric cancer and bladder cancer[55-58]. In a recent study by Ryk et al, a long set (13 or more) of (CCTTT)n repeats were associated with a lower risk for developing bladder cancer but also with a higher risk for disease progression and cancer specific death once cancer had emerged[60]. In addition, eNOS polymorphisms have been associated to cancer risk and progression[60]. Ryk et al, has recently found a correlation between bladder cancer and both the eNOS promoter polymorphism -786T>C and the intragenic eNOS polymorphism Glu298Asp[55]. iNOS promoter (-2.6 Kb) microsatellite (CCTTT)n polymorphism has been correlated to the development and aggressiveness of bladder cancer, patients with a long set of repeats of the (CCTTT)n polymorphism had a lower risk of developing bladder cancer but a higher risk for stage progression and cancer specific death once tumour had developed[55]. The presence of elevated NO concentration and iNOS expression in the urinary bladder from BCG treated patients and patients with CIS further supports the notion that NO may be an important factor in bladder cancer biology and that the BCG effect on superficial bladder cancer may partly be due to stimulation of local NO formation[57].

Ryk et al reported that the eNOS is expressed in the bladder tumor vessels, suggesting the possible relation between eNOS and the bladder cancer. They found no increased risk of bladder cancer with Glu298Asp polymorphism. However, there was an association between the Glu298Asp and bladder tumour grade[59]. In a study by Verim et al suggested an increased risk role of eNOS GT genotype in bladder cancer susceptibility in our Turkish population[59]. Koskela et al reported that the iNOS is found to be localized to the urothelium and macrophages underlying it and their study also confirms elevated levels of endogenously formed NO and increased mRNA expression and protein levels for iNOS in patients with BCG treated bladder cancer[59]. In vivo studies result provides evidence for frequent iNOS protein expression in TCC. In addition, Their observations indicate that overexpression of iNOS expression may be one of the early events in the carcinogenesis of TCC[59]. Some results suggest that various urinary bladder lesions alter the normal differentiation pathway of urothelial superficial cells, which induces the expression of NO in mitochondria of partially differentiated cells[60].

Recently published study showed a strong relationship between the eNOS4a/b polymorphism and superficial bladder cancer. Univariate analyses revealed that the eNOS4a/b polymorphism predicted recurrence and progression. The authors suggested that a genotype containing the ‘a’ allele of the eNOS4a/b polymorphism may be a risk factor for bladder cancer. Furthermore, patients harboring the ‘aa’ plus ‘ab’ genotype are more likely to experience tumor recurrence and progression. In addition, compared to patients with the ‘b’ allele, those with the eNOS4a/b gene polymorphism ‘a’ allele or at least 1 mutated ‘a’ allele (aa or ab) were more susceptible to high grade disease (p=0.007) and bladder tumor invasiveness[62].

CONCLUSION
Nitric oxide (NO) is an important biological molecule with a variety of functions. NO may have both pro- and antitumor functions. NO could take part in tumour development and progression. However, for researchers, the problems of NO chemistry in the tumor environment, NO output, NO protumor activity, and the target cell type remain to be further investigated by moving from in vitro biology to more relevant animal models. NOS select inhibitors and their possible use for the prevention and treatment of various cancers. NO may be involved in the anti-tumor mechanism that BCG exerts on bladder cancer cells.

CONFLICT OF INTERESTS
The authors declare no conflict of interest.

REFERENCES
1. Demirel F, Cakan M, Yalçinkaya F, Topcuoglu M, Altug U. The association between personal habits and bladder cancer in Turkey. Int Urol Nephrol, 2008;40: 643-647.
2. Botelho MC, Oliveira PA, Lopes C, Correia da Costa JM, Machado JC. Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium. Urol Oncol. 2011 Nov-Dec;29(6):809-14
3. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isoforms. Characterization, purification, molecular cloning, and functions. Hypertension, 1994; 23:1121-1131.
4. Pance A. Nitric oxide and hormones in breast cancer: allies or enemies? Future Oncol. 2006;2: 275-288.
5. Yang J, Ambrosone CB, Hong CC, Ahn J, Rodriguez C, Thun MJ, Calle EE. Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and risk of post-menopausal breast cancer. Carcinogenesis 2007,28:1247-1253
6. Ryk C, Wiklund NP, Nyberg T, de Verdier PJ. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary-bladder cancer. Nitric Oxide, 2011;25: 338-343
7. Arikano S, Cacina C, Guler E, Çulcu S, Tuna G, Yaylım-Eraltan I, et al. The effects of NOS3 Glu298Asp variant on colorectal cancer risk progression, molecular cloning, and functions. Hypertension, 1994; 23:1121-1131.
8. Terrazzino S, La Mattina P, Masini L, Caltavuturo T, Gambaro G, Canonic PL, Genazzani AA, Krengli M. Common variants of eNOS and XRCC1 genes may predict acute skin toxicity in breast cancer patients receiving radiotherapy after breast conserving surgery. Radiother Oncol, 2012; 103: 199-205.
9. Koskela RL. On the role of nitric oxide in lower urinary tract disease. Available from: URL: http://openarchive.ki.se/xmlui/bitstream/handle/10616/40549/Thesis_Lotta_Renstr%C3%B6m_Koskela.pdf?sequence=1
10. Janakiram NB, Rao CV. iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med Chem. 2012; 4(17):
2193-2204.

11. Lancaster JR Jr, Xie K. Tumors face NO problems? Cancer Res. 2006; 66: 6459-6462.

12. Drapier JC, Bouton C. Modulation by nitric oxide of metalloprotein regulatory activities. Bioessays, 1996;18: 549-556.

13. Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Bioess. Rep. 2004; 24, 452-474.

14. Shen YH, Wang XL, Wilken DE. Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett. 1998; 433: 125-131.

15. Polte T, Oberle S, Schröder H. Nitric oxide protects endothelial cells from tumor necrosis factor-alpha-mediated cytotoxicity: possible involvement of cyclic GMP. FEBS Lett. 1997; 409: 46-48.

16. Wink DA, Cook JA, Pacellini R, DeGraff W, Gamson J, Liebmann J, Krishna MC, Mitchell JB. The effect of various nitric oxide donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch. Biochem. Biophys. 1996; 331: 241-248.

17. Wink DA, Spragg KS, Maragos CM, Elsperku RK, Misera M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science, 1991;254;1001-1003.

18. Amba S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J., 1997; 11: 443-448.

19. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol., 2001; 2: 149-156.

20. Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 1997; 57, 3365-3369.

21. Marsden PA, Heng HH, Scherer NW, Stewart RJ, Hall AV, Shi YM, Tsai LA, Spragg KS. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488.

22. Kishimoto J, Spurr N, Liao M, Lizhi L, Emson P, Xu W. Localization of brain nitric oxide synthase (NOS) to human chromosome 12. Genomics. 1992;14(3):802-804.

23. Chartrain NA, Geller DA, Kottt PF, Sitrin NF, Nussler AK, Hoffman EP, Billiar TR, Hutchinson NJ, Mudgett JS. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem. 1994;269(9):6765-6772.

24. Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 2001; 154: 521-527.

25. Förstermann U, Münzel T. Endothelial nitric oxide synthase in coronary artery disease. Heart 2002; 87: 525-528.

26. Wang L, Shi GG, Yeo JC, Gong W, Wei D, Wu TT, Ajani JA, Huang YK, Chou HY, Chen CJ. Genetic polymorphisms of oxidative and antioxidant enzymes and arsenic-related hypertension. J. Toxicol. Environ. Health, 2005; 68: 1471-1484.

27. Wink DA, Vodovoz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted role of nitric oxide in cancer. Carcinogenesis, 1998;19:711-721.

28. Jenkins DC, Charles JG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Enson PC, Moncada S. Roles of nitric oxide in tumor growth. Proc. Natl Acad. Sci. USA, 1995;92:4392-4396.

29. Hirst D, Robson T. Nitric oxide in cancer therapeutics: interaction with cytokotoxic chemotherapy. Curr Pharm Des. 2010;16(4):411-420.

30. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007 May;27(3):317-352.

31. Wu X, Wang ZF, Xu Y, Ren H, Bl Sk, ZB. Association Between Three eNOS Polymorphisms and Cancer Risk: a Meta-analysis. Asian Pac J Cancer Prev. 2014;15(3):5317-24.

32. Carpenter AW, Schoenfisch MH. Nitric Oxide Release Part II. Therapeutic Applications. Chem Soc Rev. 2012; 41: 3742-3752.

33. Ozurtur E, Balot O, Pehlivan S, Ugur MG, Ozkan Y, Sever T, Namduru E, Kül S. Association of endothelial nitric oxide synthase gene polymorphisms with endometrial carcinoma: a preliminary study. J Turkish-German Gynecol Assoc 2011; 12: 229-233.

34. Teder Ünal M, Karabulut HG, Gümiş-Akay G, Dölen Y, Elhan A, Tükün A, Ünal AE. Endothelial nitric oxide synthase gene polymorphism in gastric cancer. Turk J Gastroenterol 2010; 21 (4): 338-344.

35. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev. 2002 Aug;11(4):343-350.

36. Botelho MC, Costa C, Silva S, Costa S, Dhawan A, Oliveira PA, Teixeira JP. Effects of titanium dioxide nanoparticles in human gastric epithelial cells in vitro. Biomed Pharmacother. 2014 Feb;68(1):59-64.

37. Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, Chanock S, Huang WY, Hayes RB. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009, 30: 621-625.

38. Thomae AR, Nakayama DK, Billiar TR, Simmons RL, Pitt BR, Davies P. The effect of nitric oxide on fetal pulmonary artery smooth muscle growth. J Surg Res. 1995 Sep;59(3):337-343.

39. Morcos E, Jansson OT, Morcos E, Adolfsson J, Kratz G, Wiklund NP. Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 1999 Jun;53(6):1252-1257.

40. Jansson OT, Moros E, Brundin L, Lundberg JO, Adolsson J, Söderhäll M, Wiklund NP. The role of nitric oxide in bacillus Calmette-Guerin mediated anti-tumour effects in human bladder cancer. Br J Cancer. 1998 Sep;78(5):588-592.

41. Lin Z, Chen S, Ye C, Zhu S. Nitric oxide synthase expression in...
human bladder cancer and its relation to angiogenesis. Urol Res. 2003 Aug;31(4):232-235.

49. NSwana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 1999; 161:630-634.

50. Hayashi H, Kuwahara M, Fujisaki N, Furihata M, Ohtsuki Y, Kagawa S. Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol. Rep. 2001; 8:1275-1279.

51. Wolf H, Haeckel C, Roessner A. Inducible nitric oxide synthase expression in human urinary bladder cancer. Virch. Arch. 2000; 437:662-666.

52. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology. 1999; 54:416-419.

53. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H. Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett. 2005; 217(2):197-202.

54. Shen CH, Wang YH, Wang WC, Jou YC, Hsu HS, Hsieh HY, Chiou HY. Inducible nitric oxide synthase promoter polymorphism, cigarette smoking, and urothelial carcinoma risk. Urology. 2007 May;69(5):1001-1006.

55. Ryk C, Steineck G, Wiklund NP, Nyberg T, de Verdier PJ. The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis. J Urol. 2010 Nov;184(5):2150-2157.

56. Marangoni K, Aranjo TG, Neves AF, Goulart LR. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Cancer. 2008 Sep 29;8:273.

57. Hosseini A, Kosek LR, Ehrén I, Aguilar-Santelises M, Sirsjo A, Wiklund NP. Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. Nitric Oxide. 2006 Dec;15(4):337-343.

58. Verim L, Toptas B, Ozkan NE, Cacina C, Turan S, Korkmaz G, Yaylim I. Possible Relation between the NOS3 Gene GLU298ASP Polymorphism and Bladder Cancer in Turkey. Asian Pacific J Cancer Prev, 2013; 14 (2):665-668.

59. Koskela LR, Poljakovic M, Ehrén I, Wiklund NP, de Verdier PJ. Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer. Nitric Oxide. 2012 Oct 15;27(3):185-191.

60. Romih R, Korosec P, Sedmak B, Jezernik K. Mitochondrial localization of nitric oxide synthase in partially differentiated urothelial cells of urinary bladder lesions. Appl Immunohistochem Mol Morphol. 2008 May;16(3):239-245.

61. Faustino-Rocha AI, Rodrigues D, da Costa RG et al. Trihalomethanes in Liver Pathology: Mitochondrial Dysfunction and Oxidative Stress in the Mouse. Environ Toxicol. 2015 Jan 9. doi: 10.1002/tox.22110. [Epub ahead of print]

62. Amasyali AS, Kucukgergin C, Erdem S, Sanli O, Seckin S, Nane I. Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases. J Urol. 2012 Dec;188(6):2398-2403.

Peer reviewers: Monica C. Botelho, PhD, Department of Health Promotion and Chronic Diseases, National Institute of Health Dr. Ricardo Jorge, Rua Alexandre Herculano, 321, 4000-055 Porto, Portugal; Mohammad Ali Mohammad, Prof Medical Biochemistry and Molecular Biology, Cancer Biology Dept., National Cancer Institute, Foum Al Khalieg, Cairo, Egypt.